Novartis Facing Pipeline Test

Note: This section contains information in English only.
Source: Dukascopy Bank SA
Novartis investors are focused on three upcoming H2 drug trials—pelacarsen, remibrutinib, and del-desiran—with $10 billion in peak sales potential. The results are vital to justifying the company's premium valuation amid looming patent expiries.
Back to articles

Actual Topics

Mon, 20 Jul 2026 09:15:05 GMT

Ryanair Profit Misses Forecasts

Ryanair reported a lower-than-expected Q1 profit of €538 million and warned that summer fares will trend modestly down.

Mon, 20 Jul 2026 06:25:04 GMT

Gemini 3.5 Pro Delayed Google delayed Gemini 3.5 Pro past its June window d

Google delayed Gemini 3.5 Pro past its June window due to disappointing coding performance. An upgraded Gemini 3.5 Flash model is also in testing.

Mon, 20 Jul 2026 03:30:07 GMT

Apple Reclaims Top Spot

Apple overtook Nvidia to become the world's most valuable company at $4.88 trillion, driven by shifting investor confidence toward its AI monetization strategy.

To learn more about Dukascopy Bank CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.
To learn more about Dukascopy Bank Binary Options / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Dukascopy Bank CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Business Introducer and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.